Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tonlamarsen in Uncontrolled Hypertension (KARDINAL)
NCT06864104Phase 2Completed
- Sponsor
- Kardigan
- Start
- Apr 2025
- Primary completion
- Jan 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertension (HTN) comparing Tonlamarsen with Placebo (2 arms). Primary endpoints: Plasma Angiotensinogen Levels at 20 weeks and Systolic Blood Pressure at 20 weeks. Started Apr 2025; status: completed.
02
Drugs
tonlamarsen
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06864104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06864104.